Myasthenia gravis after allogeneic bone marrow transplantation for lymphoblastic lymphoma

J. E. Dowell, P. L. Moots, R. S. Stein

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A 31-year-old female with lymphoblastic lymphoma developed myasthenia gravis (MG) 26 months after receiving an allogeneic bone marrow transplant (BMT) from an HLA-identical sister. She presented with classic symptoms and electromyographic evidence of the disorder approximately 2 weeks after electing to abruptly discontinue her immunosuppressive medications. She initially responded to steroids and acetylcholinesterase inhibitors. Her subsequent course has been characterized by episodes of moderately severe weakness that respond to intravenous immunoglobulin and prednisone. This case of post-transplant MG is only the second reported to have occurred in association with BMT for lymphoblastic lymphoma. Potential risk factors for the development of post-transplant MG are discussed including underlying hematological disorder, HLA phenotype, family history of MG, the presence of chronic GVHD, and recent cessation of immune suppression.

Original languageEnglish (US)
Pages (from-to)1359-1361
Number of pages3
JournalBone Marrow Transplantation
Volume24
Issue number12
StatePublished - 1999

Fingerprint

Myasthenia Gravis
Homologous Transplantation
Bone Marrow Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Transplants
Bone Marrow
Intravenous Immunoglobulins
Cholinesterase Inhibitors
Immunosuppressive Agents
Prednisone
Steroids
Phenotype

Keywords

  • Allogeneic bone marrow transplant
  • Graft-versus-host disease
  • Lymphoblastic lymphoma
  • Myasthenia gravis

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Myasthenia gravis after allogeneic bone marrow transplantation for lymphoblastic lymphoma. / Dowell, J. E.; Moots, P. L.; Stein, R. S.

In: Bone Marrow Transplantation, Vol. 24, No. 12, 1999, p. 1359-1361.

Research output: Contribution to journalArticle

@article{ad2e1d191eae44e684db7bf0957e4150,
title = "Myasthenia gravis after allogeneic bone marrow transplantation for lymphoblastic lymphoma",
abstract = "A 31-year-old female with lymphoblastic lymphoma developed myasthenia gravis (MG) 26 months after receiving an allogeneic bone marrow transplant (BMT) from an HLA-identical sister. She presented with classic symptoms and electromyographic evidence of the disorder approximately 2 weeks after electing to abruptly discontinue her immunosuppressive medications. She initially responded to steroids and acetylcholinesterase inhibitors. Her subsequent course has been characterized by episodes of moderately severe weakness that respond to intravenous immunoglobulin and prednisone. This case of post-transplant MG is only the second reported to have occurred in association with BMT for lymphoblastic lymphoma. Potential risk factors for the development of post-transplant MG are discussed including underlying hematological disorder, HLA phenotype, family history of MG, the presence of chronic GVHD, and recent cessation of immune suppression.",
keywords = "Allogeneic bone marrow transplant, Graft-versus-host disease, Lymphoblastic lymphoma, Myasthenia gravis",
author = "Dowell, {J. E.} and Moots, {P. L.} and Stein, {R. S.}",
year = "1999",
language = "English (US)",
volume = "24",
pages = "1359--1361",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Myasthenia gravis after allogeneic bone marrow transplantation for lymphoblastic lymphoma

AU - Dowell, J. E.

AU - Moots, P. L.

AU - Stein, R. S.

PY - 1999

Y1 - 1999

N2 - A 31-year-old female with lymphoblastic lymphoma developed myasthenia gravis (MG) 26 months after receiving an allogeneic bone marrow transplant (BMT) from an HLA-identical sister. She presented with classic symptoms and electromyographic evidence of the disorder approximately 2 weeks after electing to abruptly discontinue her immunosuppressive medications. She initially responded to steroids and acetylcholinesterase inhibitors. Her subsequent course has been characterized by episodes of moderately severe weakness that respond to intravenous immunoglobulin and prednisone. This case of post-transplant MG is only the second reported to have occurred in association with BMT for lymphoblastic lymphoma. Potential risk factors for the development of post-transplant MG are discussed including underlying hematological disorder, HLA phenotype, family history of MG, the presence of chronic GVHD, and recent cessation of immune suppression.

AB - A 31-year-old female with lymphoblastic lymphoma developed myasthenia gravis (MG) 26 months after receiving an allogeneic bone marrow transplant (BMT) from an HLA-identical sister. She presented with classic symptoms and electromyographic evidence of the disorder approximately 2 weeks after electing to abruptly discontinue her immunosuppressive medications. She initially responded to steroids and acetylcholinesterase inhibitors. Her subsequent course has been characterized by episodes of moderately severe weakness that respond to intravenous immunoglobulin and prednisone. This case of post-transplant MG is only the second reported to have occurred in association with BMT for lymphoblastic lymphoma. Potential risk factors for the development of post-transplant MG are discussed including underlying hematological disorder, HLA phenotype, family history of MG, the presence of chronic GVHD, and recent cessation of immune suppression.

KW - Allogeneic bone marrow transplant

KW - Graft-versus-host disease

KW - Lymphoblastic lymphoma

KW - Myasthenia gravis

UR - http://www.scopus.com/inward/record.url?scp=0033379175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033379175&partnerID=8YFLogxK

M3 - Article

C2 - 10627649

AN - SCOPUS:0033379175

VL - 24

SP - 1359

EP - 1361

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -